YCANTH Faster Than Vehicle for Molluscum Clearance in CAMP Trials

Key Takeaways

• Among people with molluscum contagiosum, in the pooled Phase 3 CAMP trials, Verrica reported an approximately fourfold faster rate of first complete clearance with YCANTH than with vehicle.
• Cumulative complete clearance by day 84 was higher with YCANTH than with vehicle.
• Verrica reported faster clearance with YCANTH regardless of disease duration.

Verrica pooled data after completion of the Phase 3 CAMP-1 and CAMP-2 trials in people with molluscum contagiosum. Its post-hoc pooled analysis compared YCANTH (VP-102) with vehicle on time to first complete clearance and examined disease duration as a factor in treatment response, with posters scheduled for the Fall Clinical Dermatology Conference (October 8–11, 2026).

Verrica characterized the rate of first complete clearance with VP-102 as approximately fourfold faster than with vehicle, reporting a hazard ratio (HR) of 4.06 and a 95% confidence interval (CI) of 2.94–5.74. Sensitivity analyses yielded similar treatment-effect estimates.

Kaplan–Meier estimates of cumulative first complete clearance by day 84 were 60.1% with VP-102 and 19.9% with vehicle. Verrica also said more YCANTH recipients than vehicle recipients achieved complete clearance at each measured time point

Clinician Questions

Which ages are covered by the U.S. YCANTH approval for molluscum contagiosum?

YCANTH (VP-102) is FDA-approved in the United States to treat molluscum contagiosum in adults and children aged 2 years and older.

How is YCANTH administered for molluscum contagiosum?

YCANTH (VP-102) is a healthcare-professional-administered topical cantharidin drug-device combination supplied with a single-use applicator for targeted dosing of molluscum contagiosum lesions.